Anis Feki

Dr. Anis Feki


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RHRima Hajjar
Rima Hajjar
SHSana Hatoum
Sana Hatoum
SMSerge Mattar
Serge Mattar
GMGaby Moawad
Gaby Moawad
Jean Marc AyoubiJean Marc Ayoubi
Jean Marc Ayoubi
LGLabib Ghulmiyyah
Labib Ghulmiyyah
Background/Objectives: Endocrine disruptors are ubiquitous agents in the environment and are present in everyday consumer products. These agents can interfere with the endocrine system, and subsequently the reproductive system, especially in pregnancy. Increasing research has been conducted to discover and describe the health effects of these agents on humans, including pregnant women, their fetuses, and the placenta. This review discusses prenatal exposure to various endocrine disruptors focusing on Bisphenols, Phthalates, Organophosphates, and Perfluoroalkyl substances, and their effects on pregnancy and fetal development. Methods: We reviewed the literature via PubMed and EBSCO databases and included the most relevant studies. Results: Our findings reveal that several negative health outcomes were linked to endocrine disruptors. However, despite the seriousness of this topic and the abundance of research on these agents, it remains challenging to draw strong conclusions about their effects from the available studies. This does not allow for strong, universal guidelines and might result in poor patient counseling and heterogeneous approaches to regulating endocrine disruptors. Conclusion: The urgency of the matter calls for urgent efforts, as more studies are needed in this realm, to protect pregnant patients ultimately and in the long term, society.

16 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PCPanagiotis Cherouveim
Panagiotis Cherouveim
ECEsra Cetin
Esra Cetin
STShagun Tuli
Shagun Tuli
TLTaylor Lombard
Taylor Lombard
YYYoussef Youssef
Youssef Youssef
AFAnis Feki
Anis Feki
Pregnancies following Assisted Reproductive Technology (ART) are associated with increased risk for adverse maternal and neonatal outcomes. However, it is not clear if these associations are derived from infertility or fertility treatment itself. The goal of this review is to investigate if there are differences in maternal and neonatal outcomes between pregnancies conceived through either intrauterine insemination (IUI) or in vitro fertilization (IVF) to obtain an estimate of the effect of the fertility treatment. We retrospectively reviewed the literature for original studies comparing maternal and neonatal outcomes in pregnancies following IUI to those following IVF. To reduce confounding, our synthesis focuses on singleton gestations, while excluding donor sperm and multifetal pregnancies. Findings are interpreted alongside recent ART vs. non-ART evidence to contextualize potential treatment-related effects. Most studies suggest no difference in maternal outcomes, but outcomes were inconsistently reported between studies. Neonatal outcomes were more consistently reported, and there was less variation between results. Current evidence does not suggest a large difference in neonatal outcomes between IVF and IUI. However, almost all studies have significant limitations that hinder clear conclusions. To summarize, even though the current literature does not suggest significant differences in maternal and neonatal outcomes following IVF and IUI, further high-quality studies are needed to establish a definite correlation.

Verified
Journal Article
Open access
PDF file
PCPanagiotis Cherouveim
Panagiotis Cherouveim
ECEsra Cetin
Esra Cetin
CSCeline Sooknarine
Celine Sooknarine
STShagun Tuli
Shagun Tuli
BSBhuchitra Singh
Bhuchitra Singh
AFAnis Feki
Anis Feki
Assisted reproductive technology (ART) is increasingly utilized worldwide, yet concerns remain regarding its potential association with breast and gynecological malignancies and the safety of fertility-preservation strategies in cancer survivors. Ovarian stimulation exposes women to supraphysiologic hormone levels, raising questions about cancer risk, particularly for hormone-sensitive tumors. Current evidence, however, is largely reassuring. Registry-based studies and meta-analyses demonstrate no consistent increase in breast or endometrial cancer following ART, although endometrial cancer risk remains inconclusive despite large new cohorts. Cervical cancer has not been linked to ART exposure. For ovarian cancer, risk appears primarily driven by underlying infertility, parity, and endometriosis rather than ART itself, and no excess risk is observed among BRCA mutation carriers. In parallel, fertility preservation (FP) has become an integral component of gynecologic oncology care for reproductive-aged women. Strategies including cryopreservation of oocytes, embryos, or ovarian tissue, as well as fertility-sparing surgery or hormonal therapy, can be safely pursued in carefully selected early-stage cancers. Pregnancy and livebirth rates vary by diagnosis: outcomes are favorable after breast and cervical cancers, more limited in endometrial cancer due to endometrial receptivity challenges, and possible but less predictable in ovarian cancer, where stage and histology guide feasibility. Available observational evidence does not suggest a clear increase in recurrence risk among carefully selected patients, although evidence remains limited and long-term follow-up is needed. Overall, current data suggest ART is safe when individualized to patient and tumor characteristics, highlighting the importance of proactive fertility counseling, modified stimulation protocols, and multidisciplinary care to optimize oncologic and reproductive outcomes.